Core Insights - The forum discussed the transition of the biopharmaceutical industry from "quantitative change" to "qualitative change" and the role of AI in driving high-quality development [2] Group 1: Industry Development Directions - The integration of technology and precision medicine is a key development direction in the global biopharmaceutical industry [2] - AI technology can significantly shorten the research and development cycle for in vitro diagnostic reagents from approximately 5 years to 18 months [2] - The combination of genomics and multimodal technologies is advancing precision medicine, with applications in cell therapy and CRISPR gene editing for treating blood cancers and rare diseases [2] Group 2: Impact of AI Technology - AI is viewed as a core driving force for the development of the biopharmaceutical industry [3] - The deep integration of disciplines is a significant trend, with AI and big data playing a crucial role in drug development and clinical research [3] - AI is transforming molecular design processes, enabling the design of new molecules that do not exist in nature, thereby greatly enhancing research and development efficiency [3] Group 3: Challenges and Opportunities - Regulatory and payment frameworks are identified as major challenges for the development of precision medicine [4] - The emergence of numerous new technologies raises higher regulatory demands, necessitating a balance between promoting development and risk prevention [4] - Opportunities exist in early screening, diagnosis, and treatment in areas such as neurodegenerative diseases and chronic disease management, significantly improving patient quality of life [4] Group 4: Collaborative Efforts for Quality Development - The transition from "quantitative change" to "qualitative change" in the biopharmaceutical industry requires collaboration among various stakeholders [4] - Data quality is crucial for AI applications, necessitating the collection of scientific-grade big data [4] - As technology continues to advance, regulatory frameworks improve, and international cooperation deepens, the biopharmaceutical industry is expected to achieve higher quality development, benefiting human health [4]